It’s so special to be playing for a purpose, the purpose being this incredible mission,” Eddie Vedder tells TODAY.com.

Announced Positive Clinical Data for Adult and Pediatric Netherton Patients ASHBURN, Va., May 13, 2025 (GLOBE NEWSWIRE) -- ...

EMERYVILLE, Calif. , May 13, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator ...

Abeona’s deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.

Abeona Therapeutics Inc. (Nasdaq: ABEO), a Cleveland-based biotech company, announced Monday, May 12, that it has entered an ...

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

Spring has been bountiful at Cleveland's Abeona Therapeutics. | As Abeona gears up for the commercial rollout of Zevaskyn, ...

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of ...

A Mayo woman who suffers from a rare, genetic skin disease will abseil from the roof of Croke Park to fundraise for a charity that supports people with Epidermolysis Bullosa (EB).Nineteen-year-old ...

Epidermolysis Bullosa, also colloquially known as butterfly skin disease, a rare genetic condition that makes your skin very ...

Krystal Biotech, Inc.’s KRYS share price has dipped by 12.19%, which has investors questioning if this is right time to buy.

Shares of Krystal Biotech slid after the company's first-quarter earnings missed Wall Street expectations. The stock was down 14% at $139.03, putting shares 11% in the red for the year.